Dr Lal PathLabs to buy 70% of Gujarat-based SN Genelab for Rs 168 crore
Dr Lal PathLabs has approved the acquisition of a 70% stake in SN Genelab, a Gujarat-based diagnostics and genomics company, for about Rs 168 crore. The deal also includes a performance-linked earn-out capped at Rs 31.5 crore, strengthening its advanced diagnostics and genomics portfolio.
What happened
Dr. Lal PathLabs · Dr Lal PathLabs approved the acquisition of a 70% stake in Gujarat-based diagnostic genomics company SN Genelab for about Rs 168 crore, plus
Key facts
- 70% stake
- Rs 168 crore
- Rs 31.5 crore earn-out cap
- Rs 57.96 crore FY26 turnover
- Rs 53.36 crore FY25 turnover
- Rs 43.27 crore FY24 turnover
Why this matters
The 70% stake structure gives Dr Lal PathLabs control while retaining seller alignment through an earn-out, illustrating a targeted bolt-on approach to building advanced-diagnostics capabilities ahead of the November 2026 close.
What to watch
- Regulatory approvals and closing progress ahead of the November 30, 2026 target.
- Disclosure of SN Genelab revenue, EBITDA, growth milestones and the specific conditions governing the Rs 31.5 crore earn-out.
- Growth in advanced-diagnostics and genomics test volumes, average revenue per patient and share of specialized tests in Dr Lal PathLabs' mix.
- Evidence of successful Gujarat network integration, including new collection centres, hospital tie-ups and cross-referral volumes.
- Margin trajectory and integration costs in the first four to six quarters after completion.
- Competitive responses from Metropolis, Thyrocare, hospital chains and genomics-focused diagnostics providers, especially through pricing or expanded test menus.
- Retain SN Genelab's scientific leadership and key referring-doctor relationships while standardizing quality systems, reporting formats and compliance processes.
- Launch SN Genelab's genomics and advanced-diagnostics panels across Dr Lal PathLabs' national collection-centre and B2B hospital network.
- Bundle genetic testing with oncology, fertility, pregnancy, preventive-health and chronic-disease diagnostic pathways.
- Invest in clinician outreach, genetic-counselling partnerships and digital report interpretation to improve adoption of complex tests.
- Pursue further bolt-on acquisitions or partnerships in specialized pathology, molecular diagnostics and regional laboratory networks if integration validates the model.